FDA Approves NPS’ Natpara With Population And Distribution Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
Osteosarcoma findings in rat studies led to a boxed warning and stringent Risk Evaluation and Mitigation Strategy for the hypoparathyroidism treatment. NPS Pharmaceuticals’ post-marketing requirements include a clinical trial of alternative doses or dosing regimens.